Literature DB >> 7969932

Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry.

R J Beninger1, A M Colton, J L Ingles, K Jhamandas, R J Boegman.   

Abstract

Previous results suggest that the tryptophan metabolite, picolinic acid may have the unusual properties of antagonizing the neurotoxic but not the neuroexcitant effects of another tryptophan metabolite, quinolinic acid in the central nervous system. The present experiments tested this possibility utilizing behavioural and tyrosine hydroxylase immunohistochemical techniques. In the first series of experiments, rats received injections of relatively high concentrations of 6-hydroxydopamine (12 micrograms in 1 or 2 microliters), quinolinic acid (120 nmol in 0.5 microliters), picolinic acid (480 nmol in 0.5 microliters) or co-treatments (0.5 microliters) with quinolinic (120 nmol) plus picolinic acid (480 nmol) into the region of the substantia nigra. Results revealed that 6-hydroxydopamine and quinolinic acid alone produced a large loss of tyrosine hydroxylase-positive cells in the pars compacta of the substantia nigra. Behavioural results for all 6-hydroxydopamine (n = 10) and for some quinolinate-treated rats (n = 5) revealed ipsi- and contraversive circling following amphetamine (1 mg/kg, i.p.) and apomorphine (0.5 mg/kg, s.c.), respectively, consistent with unilateral loss of dopamine cells in the substantia nigra. The remaining quinolinate-treated rats (n = 9) circled ipsiversively following either stimulant suggesting damage to the pars reticulata. Groups treated with picolinic acid alone (n = 6) or co-injected (n = 6) showed no loss of tyrosine hydroxylase-positive cells in the substantia nigra and no circling response to the stimulants. In the second series of experiments, low concentrations of quinolinic acid (2.5, 5.0, 7.5 nmol), picolinic acid (10, 20, 30 nmol), or the two together (7.5 plus 30 nmol, respectively) were microinjected (0.5 microliter) into the dorsal striatum and circling behaviour evaluated. These results revealed dose-dependent contralateral circling with either quinolinate or picolinate; co-injection of the two tryptophan metabolites also produced contralateral circling. It was concluded that picolinic acid blocks the neurotoxic but not the neuroexcitant effects of quinolinic acid.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969932     DOI: 10.1016/0306-4522(94)90438-3

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  24 in total

1.  Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid.

Authors:  Buranee Kanchanatawan; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; Heidi Ormstad; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-02-08       Impact factor: 5.590

Review 2.  Emerging roles of pericytes in the regulation of the neurovascular unit in health and disease.

Authors:  Jeremy Hill; Slava Rom; Servio H Ramirez; Yuri Persidsky
Journal:  J Neuroimmune Pharmacol       Date:  2014-08-14       Impact factor: 4.147

3.  Ethyl glucuronide, a marker of alcohol consumption, correlates with metabolic markers of oxidant stress but not with hemolysis in stored red blood cells from healthy blood donors.

Authors:  Angelo D'Alessandro; Xiaoyun Fu; Julie A Reisz; Mars Stone; Steve Kleinman; James C Zimring; Michael Busch
Journal:  Transfusion       Date:  2020-05-08       Impact factor: 3.157

4.  Excitotoxicity of quinolinic acid: modulation by endogenous antagonists.

Authors:  K H Jhamandas; R J Boegman; R J Beninger; A F Miranda; K A Lipic
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

5.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

Review 6.  Glutaric aciduria type I and kynurenine pathway metabolites: a modified hypothesis.

Authors:  S Varadkar; R Surtees
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 7.  The involvement of astrocytes and kynurenine pathway in Alzheimer's disease.

Authors:  Ka Ka Ting; Bruce Brew; Gilles Guillemin
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

8.  The kynurenine pathway and inflammation in amyotrophic lateral sclerosis.

Authors:  Yiquan Chen; Roger Stankovic; Karen M Cullen; Vincent Meininger; Brett Garner; Sarah Coggan; Ross Grant; Bruce J Brew; Gilles J Guillemin
Journal:  Neurotox Res       Date:  2009-11-18       Impact factor: 3.911

9.  Stored RBC metabolism as a function of caffeine levels.

Authors:  Angelo D'Alessandro; Xiaoyun Fu; Julie A Reisz; Tamir Kanias; Grier P Page; Mars Stone; Steve Kleinman; James C Zimring; Michael Busch
Journal:  Transfusion       Date:  2020-05-11       Impact factor: 3.157

Review 10.  Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes.

Authors:  Nady Braidy; Jade Berg; James Clement; Fatemeh Khorshidi; Anne Poljak; Tharusha Jayasena; Ross Grant; Perminder Sachdev
Journal:  Antioxid Redox Signal       Date:  2018-05-11       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.